These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. Subtype-Specific Interactions and Prognosis in Cardiac Amyloidosis. Sperry BW; Vranian MN; Hachamovitch R; Joshi H; Ikram A; Phelan D; Hanna M J Am Heart Assoc; 2016 Mar; 5(3):e002877. PubMed ID: 27013539 [TBL] [Abstract][Full Text] [Related]
15. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. Yamamoto H; Yokochi T ESC Heart Fail; 2019 Dec; 6(6):1128-1139. PubMed ID: 31553132 [TBL] [Abstract][Full Text] [Related]
16. [Suspected cardiac amyloidosis - diagnostic steps for evaluation]. Feldmann K; Hamm CW; Aßmus B Dtsch Med Wochenschr; 2020 Aug; 145(16):1162-1168. PubMed ID: 32791553 [TBL] [Abstract][Full Text] [Related]
17. Sex Differences in Transthyretin Cardiac Amyloidosis: Unraveling the Complexities in Epidemiology, Pathophysiology, Diagnosis, and Treatment. Vilches S; Martínez-Avial M; Méndez I; Gómez González C; Espinosa MÁ Curr Heart Fail Rep; 2024 Aug; 21(4):344-353. PubMed ID: 38775878 [TBL] [Abstract][Full Text] [Related]
18. Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature. Adam RD; Coriu D; Jercan A; Bădeliţă S; Popescu BA; Damy T; Jurcuţ R ESC Heart Fail; 2021 Aug; 8(4):2380-2396. PubMed ID: 34089308 [TBL] [Abstract][Full Text] [Related]
19. The importance of pathways to facilitate early diagnosis and treatment of patients with cardiac amyloidosis. Kwok CS; Moody WE Ther Adv Cardiovasc Dis; 2023; 17():17539447231216318. PubMed ID: 38099406 [TBL] [Abstract][Full Text] [Related]
20. Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement. Rigopoulos AG; Ali M; Abate E; Torky AR; Matiakis M; Mammadov M; Melnyk H; Vogt A; de Vecchis R; Bigalke B; Wohlgemuth W; Mavrogeni S; Noutsias M Heart Fail Rev; 2019 Jul; 24(4):521-533. PubMed ID: 30790171 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]